शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ZIMLABNSEZim Laboratories LimitedHighNeutral
Announced Thu, 8 May, 2025 · 18:14 IST

Zim Laboratories Limited has informed the Exchange about completion of acquisition of Shares

Listed Co AcquisitionStrategic Transactions View source PDFExplain this filing

ZIMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.0%Reaction day
₹82.11
prior close
₹83.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+1.1% vs market

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.5
10m
-0.3
15m
-0.3
30m
-0.2
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
+1.0-0.1+1.1
Next day
+5.2+4.5+0.7
2d
+7.1+6.2+0.8
3d
+11.1+7.9+3.1
4d
+11.6+9.0+2.6
5d
+12.0+9.9+2.2
1w
+14.3+10.0+4.3
15d
+9.2+13.1-3.9
1m
+24.0+15.5+8.4
2m
+41.3+16.8+24.4
3m
-8.0+11.3-19.4
UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zim Laboratories Limited has completed the process of investing Euro 1,50,000 in the equity shares of its wholly owned subsidiary, SIA ZIM Laboratories Limited. This follows the company's earlier disclosure dated 30 September 2024 about the planned investment of up to Euro 1,50,000 in the subsidiary. After this investment, Zim Laboratories continues to hold 100% of the total share capital of SIA ZIM Laboratories Limited. The filing has been made under Regulation 30 of SEBI LODR to keep the exchanges informed of the completion.

Likely market impact

This is a routine capital infusion into an already wholly owned subsidiary and does not change the ownership structure. The financial impact on Zim Laboratories' consolidated position is expected to be minor, and there is no direct material effect on the stock price from this transaction.